BETAXOLOL tablet, film coated

Država: Sjedinjene Američke Države

Jezik: engleski

Izvor: NLM (National Library of Medicine)

Aktivni sastojci:

BETAXOLOL HYDROCHLORIDE (UNII: 6X97D2XT0O) (BETAXOLOL - UNII:O0ZR1R6RZ2)

Dostupno od:

PuraCap Laboratories LLC

INN (International ime):

BETAXOLOL HYDROCHLORIDE

Sastav:

BETAXOLOL HYDROCHLORIDE 10 mg

Administracija rute:

ORAL

Tip recepta:

PRESCRIPTION DRUG

Terapijske indikacije:

Betaxolol is indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly thiazide-type diuretics. Betaxolol is contraindicated in patients with known hypersensitivity to the drug. Betaxolol is contraindicated in patients with sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure. (see Warnings).

Proizvod sažetak:

Betaxolol Tablets USP, 10 mg* contains 10 mg betaxolol hydrochloride (equivalent to 8.94 mg betaxolol) are white, round biconvex, film-coated tablets, debossed “Є ” above and “38” below bisect on one side and plain on the other side. They are supplied as: NDC 24658-700-01 Bottles of 100 Tablets Betaxolol Tablets USP, 20 mg* contains 20 mg betaxolol hydrochloride (equivalent to 17.88 mg betaxolol) are white, round biconvex, film-coated tablets, debossed “Є ” above “39” on one side and plain on the other side. They are supplied as: NDC 24658-701-01 Bottles of 100 Tablets Store at 20°–25°C (68°–77°F) [See USP Controlled Room Temperature]. Distributed by: PuraCap Laboratories, LLC DBA Blu Pharmaceuticals Franklin, KY 42134 USA 1-877-264-0258 Manufactured in USA Issued August 2016 MF038ISS08/16 OE2568

Status autorizacije:

Abbreviated New Drug Application

Svojstava lijeka

BETAXOLOL- BETAXOLOL TABLET, FILM COATED
PURACAP LABORATORIES LLC
----------
BETAXOLOL TABLETS USP, FILM-COATED
RX ONLY
DESCRIPTION
Betaxolol is a β -selective (cardioselective) adrenergic receptor
blocking agent available as 10-mg and
20-mg tablets for oral administration. Betaxolol is chemically
described as 2-propanol,1-[4-[2-
(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-,hydrochloride,(±).
It has the following
chemical structure:
Betaxolol hydrochloride is a water-soluble white crystalline powder
with a molecular formula of
C
H NO •HCl and a molecular weight of 343.9. It is freely soluble in
water, ethanol, chloroform,
and methanol, and has a pKa of 9.4.
The inactive ingredients are anhydrous lactose, carnauba wax,
hypromellose, microcrystalline
cellulose, polyethylene glycol, polysorbate 80, pregelatanized starch
(corn), sodium starch glycolate,
stearic acid and titanium dioxide.
CLINICAL PHARMACOLOGY
Betaxolol is a β -selective (cardioselective) adrenergic receptor
blocking agent that has weak
membrane-stabilizing activity and no intrinsic sympathomimetic
(partial agonist) activity. The
preferential effect on β receptors is not absolute, however, and some
inhibitory effects on β
receptors (found chiefly in the bronchial and vascular musculature)
can be expected at higher doses.
PHARMACOKINETICS AND METABOLISM
In man, absorption of an oral dose is complete. There is a small and
consistent first-pass effect resulting
in an absolute bioavailability of 89% ± 5% that is unaffected by the
concomitant ingestion of food or
alcohol. Mean peak blood concentrations of 21.6 ng/ml (range 16.3 to
27.9 ng/ml) are reached between
1.5 and 6 (mean about 3) hours after a single oral dose, in healthy
volunteers, of 10 mg of betaxolol.
Peak concentrations for 20-mg and 40-mg doses are 2 and 4 times that
of a 10-mg dose and have been
shown to be linear over the dose range of 5 to 40 mg. The peak to
trough ratio of plasma concentrations
over 24 hours is 2.7. The mean elimination half-life in various
studies